课题基金 / 基金详情

Quantitative HOX Expression as Prognostic Marker in AML

Quantitative HOX Expression as Prognostic Marker in AML
定量 HOX 表达作为 AML 的预后标志物
批准号:
6845666
负责人:
HARRY A. DRABKIN
金额:
$36.01万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-01-20 至 2006-11-30

项目摘要

项目成果

HARRY A. DRABKIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Homeodomain containing genes encode transcription factors that act during development to control pattern formation, differentiation and proliferation. Based on data from our laboratory and work of others, the quantitative analysis of HOX gene expression promises to be a powerful new tool in the prognostic assessment of patients with acute myelogenous leukemia (AML). To date, characteristic chromosomal alterations have been the gold standard for prognosis in AML. However, 50 percent of AML patients lack cytogenetic changes and another 10-20 percent have alterations considered to be of intermediate importance. Thus, a majority of patients with AML lack sufficient prognostic markers upon which definitive therapeutic decisions can be made. Our studies indicate that the patterns of quantitative HOX gene expression are in near total concordance with favorable and adverse chromosomal features. In addition, these expression patterns extend to the subset of patients with normal cytogenetics and other intermediate changes and are predictive of outcome. We propose to confirm and extend our initial observations on the importance of HOX gene expression in AML. In the R21, we will refine our quantitative assays to include the complete set of HOXA, HOXB and important TALE (PBX, MEIS) family members and validate the analytic performance of these assays. We will also explore the analysis of selected extended HOX and paraHox genes in AML for inclusion in the subsequent R33. The R33 phase will determine the role of quantitative HOX expression as a prognostic marker in AML, the association of HOX expression patterns with specific chromosomal features as well as resistant or relapsed disease, and should permit us to identify the most useful subset of HOX genes based on our analysis of large numbers of patients and disease phenotypes. Lastly, we will determine whether there is a relationship between HOX expression and another new predictor of outcome involving internal tandem duplications or mutations of the FLT3 receptor. Importantly, the HOX genes are more than markers of lineage, or differentiation. Rather, they are integrally involved in the pathogenesis of acute leukemia in both mice and man. Thus, their analysis provides insight into the disease process, and its heterogeneity, while providing new important prognostic information.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SEMA3F and ZEB1 in Lung Cancer: Therapy and Target Gene Discovery
  • 批准号:
    7448818
  • 项目类别:
  • 资助金额:
    $26.5万
  • 财政年份:
    2008
  • 负责人:
    HARRY A. DRABKIN
  • 依托单位:
DNA SEQUENCING & ANALYSIS CORE
  • 批准号:
    7229260
  • 项目类别:
  • 资助金额:
    $4.8万
  • 财政年份:
    2006
  • 负责人:
    HARRY A. DRABKIN
  • 依托单位:
Quantitative HOX Expression as Prognostic Marker in AML
  • 批准号:
    6844440
  • 项目类别:
  • 资助金额:
    $31.02万
  • 财政年份:
    2004
  • 负责人:
    HARRY A. DRABKIN
  • 依托单位:
Quantitative HOX Expression as Prognostic Marker in AML
  • 批准号:
    6999871
  • 项目类别:
  • 资助金额:
    $31.17万
  • 财政年份:
    2004
  • 负责人:
    HARRY A. DRABKIN
  • 依托单位:
海外基金